Veloxis
139 articles about Veloxis
-
Veloxis Pharmaceuticals A/S Establishes a New Warrant Programme for the Employees of the Company
11/15/2012
-
Veloxis Pharmaceuticals A/S Announces Financial Results for the First Nine Months of 2012
11/14/2012
-
Veloxis Pharmaceuticals A/S Release: Major Shareholder Announcements
11/13/2012
-
Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for Third Quarter 2012 – Results From 1 January to 30 September, 2012
11/9/2012
-
Veloxis Pharmaceuticals A/S to Present Data Differentiating LCP-Tacro® From Available Tacrolimus Formulations at the Transformational Therapies and Diagnostics in Transplantation Conference
10/10/2012
-
Veloxis Pharmaceuticals A/S, Chiesi Farmaceutici SpA Ink $47.5 Million Pact
10/5/2012
-
Veloxis Pharmaceuticals A/S Announces Financial Results for the First Half 2012, Anticipated Financing, Revised EU Regulatory Filing Strategy and Revised Outlook for 2012. Phase III Activities for LCP-Tacro™ Progressing According to Plan.
8/24/2012
-
Veloxis Pharmaceuticals A/S to Present Results from a Patient Subgroup Analysis of Once-Daily LCP-Tacro™ in Stable African-American Kidney Transplant Patients at American Transplant Congress
6/1/2012
-
Veloxis Pharmaceuticals A/S to Restructure and Cut Staff
5/23/2012
-
Veloxis Pharmaceuticals Announces Financial Results for the First Quarter 2012 In Line With Expectations, Phase III Activities for LCP-Tacro™ Progressing According to Plan
5/16/2012
-
Veloxis Pharmaceuticals A/S Completes Enrolment in LCP-Tacro(TM) 3002 Pivotal Phase III Trial in Kidney Transplant
3/29/2012
-
Veloxis Pharmaceuticals A/S Publishes Annual Report 2011
3/7/2012
-
Veloxis Pharmaceuticals A/S to Host Conference Call to Announce Annual Report 2011
3/2/2012
-
Veloxis Pharmaceuticals A/S to Present at the Cowen and Company 32nd Annual Health Care Conference
2/29/2012
-
Veloxis Pharmaceuticals A/S to Present at 14th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference
2/9/2012
-
Veloxis Pharmaceuticals A/S Announces Initiation of STRATO Study of LCP-Tacro(TM) in Kidney Transplant Recipients Experiencing Tremors
1/4/2012
-
Veloxis Pharmaceuticals A/S and Athena Drug Delivery Solutions Pvt. Ltd. Announce Partnership to Develop, Manufacture and Commercialize Its Investigational Drug Atorfen(TM) (Fenofibrate-Atorvastin Fixed Dose Combination) in Certain Emerging Markets
12/28/2011
-
Veloxis Pharmaceuticals A/S Presents LCP-Tacro(TM) Phase 3 Data at the American Society of Nephrology Annual Meeting
11/10/2011
-
Veloxis Pharmaceuticals A/S to Present at Rodman & Renshaw Annual Global Investment Conference
9/8/2011